Vol. 2 No. 3 (2013) Published
Following articles have been published in this issue:
1. A VALIDATED REVERSED-PHASE HPLC METHOD FOR THE DETERMINATION OF VILDAGLIPTIN FROM TABLET DOSAGE FORM
Abstract: A simple, rapid, precise and cost effective method has been developed and validated for determination of Vildagliptin in pharmaceutical tablet dosage form. The chromatographic separation was carried out with Shimpack VP-ODS, 150 × 4.6 mm, 5μm analytical column and mobile phase containing 0.02M phosphate buffer (pH 4.6) and acetonitrile at the ratio (80:20% v/v). pH of the buffer solution was adjusted with orthophosphoric acid. The instrumental settings include flow rate 0.7 ml/min, column temperature at 25ºC and detector wavelength of 210nm using a photodiode array detector. Theoretical plate for Vildagliptin was 6219 and tailing factor was 1.38.
2. A REVIEW ON INDIAN SAGO STARCH AND ITS PHARMACUETICAL APPLICATIONS
Abstract: Indian sago starch extracted from Tapioca roots finds its application not only as a food but also numerous commercial applications. In the present review we are discussing concisely the extraction, physiochemical properties, chemical modifications and pharmaceutical applications of Indian sago starch. The sago starch is a cheap, easily available, biodegradable and a versatile polymer. Starch has always been an important excipient in the pharmaceutical industry. It is conventionally used as a binder, disintegrant, diluent, granulating agent. It is also a starting material for many other chemicals like ethanol, glucose and cyclodextrin. Several modifications were attempted on native starch to improve and modulate its physiochemical properties.
3. DRUG DELIVERY TO THE BRAIN USING POLYMERIC NANOPARTICLES: A REVIEW
Abstract: Nanoparticle drug carriers consist of solid biodegradable particles in size ranging from 10 to 1000 nm (50–300 nm generally). The use of minute particles as drug carriers for targeted treatment has been studied over a long period of time. A selective accumulation of active substances in target tissues has been demonstrated for certain so-called nanocarrier systems that are administered bound to pharmaceutical drugs. Great expectations are placed on nanocarrier systems that can overcome natural barriers such as the blood-brain barrier (BBB) and transport the medication directly to the desired tissue and thus heal neurological diseases that were formerly incurable. Polymeric Nanoparticle have been shown to be promising carriers for CNS drug delivery due to their potential both in encapsulating drugs, hence protecting them from excretion and metabolism, and in delivering active agents across the blood – brain barrier without inflicting any damage to the barrier. Different polymers have been used and different strategies like surface modification have been done to increase the retention time of nanoparticles.
